文献速递心脑血管急症

替格瑞洛用于合并糖尿病、稳定性冠心病且有既往经皮冠状动脉介入治疗史的患者(THEMIS-PCI):一项3期、安慰剂对照、随机试验

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
PubMed 文献 · Lancet · 2019-09-01
一句话结论合并糖尿病、稳定性冠心病且有既往PCI史的患者,在阿司匹林基础上加用替格瑞洛可减少心血管死亡、心肌梗死或卒中,但大出血增加;作者认为对耐受抗血小板治疗、缺血高危且出血低危者应考虑长期双联治疗。

THEMIS-PCI是THEMIS试验中预设的既往PCI亚组,共纳入11 154例(占THEMIS总人群58%)≥50岁、2型糖尿病接受降糖药至少6个月、稳定性冠心病且有既往PCI史的患者,随机接受替格瑞洛或安慰剂(均在阿司匹林基础上),中位随访3.3年。替格瑞洛组主要疗效终点(心血管死亡、心肌梗死或卒中)7.3% vs 安慰剂组8.6%(HR 0.85,95%CI 0.74-0.97,p=0.013),无PCI史者未见此效应(p=0.76,交互p=0.16)。替格瑞洛组TIMI大出血2.0% vs 1.1%(HR 2.03,95%CI 1.48-2.76,p<0.0001),致死性出血和颅内出血两组无显著差异。净临床获益替格瑞洛组9.3% vs 11.0%(HR 0.85,95%CI 0.75-0.95,p=0.005)。作者结论认为,对合并糖尿病且有PCI史、耐受抗血小板治疗、缺血高危且出血低危的患者,应考虑长期替格瑞洛联合阿司匹林治疗。

要点

  • 合并糖尿病、稳定性冠心病且有既往PCI史者,阿司匹林加替格瑞洛较单用阿司匹林减少主要疗效终点事件(7.3% vs 8.6%,HR 0.85,95%CI 0.74-0.97)。
  • 该获益在无PCI史患者中未观察到(交互p=0.16)。
  • 替格瑞洛组TIMI大出血增加(2.0% vs 1.1%,HR 2.03,95%CI 1.48-2.76),致死性出血与颅内出血两组无显著差异。
  • 净临床获益替格瑞洛组优于安慰剂组(9.3% vs 11.0%,HR 0.85,95%CI 0.75-0.95,p=0.005),无PCI史者无此获益(交互p=0.012)。
  • 获益与距最近一次PCI的时间无关。

适用人群与场景

  • 年龄≥50岁、2型糖尿病、接受降糖药物治疗至少6个月、稳定性冠心病,且符合以下三项之一:既往PCI史、既往冠状动脉旁路移植术史、至少一支冠状动脉造影证实狭窄≥50%。
  • 本报告为其中既往PCI史亚组,共11 154例(占THEMIS总人群58%)。

处置流程与药物剂量

  • 作者认为,对合并糖尿病且有PCI史、已耐受抗血小板治疗、缺血高危且出血低危的患者,应考虑长期替格瑞洛联合阿司匹林治疗。

研究设计与关键结果

  • THEMIS-PCI为THEMIS 3期随机双盲安慰剂对照试验的预设亚组,在42个国家1315个中心进行;2014年2月17日至2016年5月24日纳入11 154例既往PCI患者,中位随访3.3年(IQR 2.8-3.8)。
  • 主要疗效终点(心血管死亡、心肌梗死或卒中,意向治疗人群):替格瑞洛组404/5558(7.3%)vs 安慰剂组480/5596(8.6%),HR 0.85(95%CI 0.74-0.97),p=0.013。
  • 无PCI史患者中未见相同效应(p=0.76,交互p=0.16)。
  • 心血管死亡:替格瑞洛组174/5558(3.1%)vs 安慰剂组183/5596(3.3%),HR 0.96(95%CI 0.78-1.18),p=0.68;全因死亡:282/5558(5.1%)vs 323/5596(5.8%),HR 0.88(95%CI 0.75-1.03),p=0.11。
  • TIMI大出血:替格瑞洛组111/5536(2.0%)vs 安慰剂组62/5564(1.1%),HR 2.03(95%CI 1.48-2.76),p<0.0001;致死性出血6/5536(0.1%)vs 6/5564(0.1%),HR 1.13(95%CI 0.36-3.50),p=0.83;颅内出血33/5536(0.6%)vs 31/5564(0.6%),HR 1.21(95%CI 0.74-1.97),p=0.45。
  • 净临床获益:替格瑞洛组519/5558(9.3%)vs 安慰剂组617/5596(11.0%),HR 0.85(95%CI 0.75-0.95),p=0.005;无PCI史患者无此获益(交互p=0.012)。
  • 获益与距最近一次PCI的时间无关。

证据类型、等级与局限

  • 证据类型:3期随机、双盲、安慰剂对照试验的预设亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对合并糖尿病、稳定性冠心病且有既往PCI史、已耐受抗血小板治疗、缺血高危且出血低危的患者,作者认为应考虑长期替格瑞洛联合阿司匹林治疗,但需权衡TIMI大出血增加(2.0% vs 1.1%)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor.

METHODS: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population).

FINDINGS: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8-3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74-0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, pinteraction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78-1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75-1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48-2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36-3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74-1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75-0·95, p=0·005, in contrast to patients without PCI where it did not, pinteraction=0·012. Benefit was present irrespective of time from most recent PCI.

INTERPRETATION: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk.

FUNDING: AstraZeneca.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019. PMID: 31484629. doi:10.1016/S0140-6736(19)31887-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。